Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.43 |
| ▸ | ATR | Q13535 | 13/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17129377 | 0.89 | CYP4F2 (0.38) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL24142066 | 0.86 | CYP4F2 (0.41) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL24031822 | 0.84 | CYP4F2 (0.41) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL26199501 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL24031809 | 0.82 | CYP4F2 (0.43) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL21759067 | 0.80 | PKM (0.36) | ALDH1A1LMNA | |
| SCHEMBL26694018 | 0.80 | CYP4F2 (0.35) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL15388480 | 0.79 | GAA (0.39) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL18209774 | 0.79 | CYP4F2 (0.35) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL17501948 | 0.79 | SMN1; SMN2 (0.36) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | ORION CORPORATION (FI) | 2026-03-24 | — | — | US | claimed |
| WO-2024257116-A1 | NOVEL POLYMORPHIC FORMS OF ASCIMINIB AND ITS PHARMACEUTICAL SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2024-12-19 | — | — | WO | claimed |
| CN-118955380-A | Pyrazole organic monomer, preparation method thereof, three-dimensional MOF material and application thereof | 云南大学 | 2024-11-15 | — | — | CN | claimed |
| CN-116041349-B | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor | 吉斯凯(苏州)制药有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-112823158-B | Process for preparing 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine | 拜耳股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2023-06-08 | — | — | US | claimed |
| CN-116041349-A | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor | 吉斯凯(苏州)制药有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4149938-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | Orion Corporation (FI) | 2023-03-22 | — | — | EP | claimed |
| CN-115605470-A | Process for preparing androgen receptor antagonists and intermediates thereof | 奥赖恩公司（FI） | 2023-01-13 | — | — | CN | claimed |
| EP-3841101-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | Bayer Aktiengesellschaft (DE) | 2021-06-30 | — | — | EP | claimed |
| CN-107428695-B | Process for preparing androgen receptor antagonists and intermediates thereof | 奥赖恩公司 | 2021-03-16 | — | — | CN | claimed |
| WO-2020039025-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | WO | claimed |
| EP-3280710-B1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORP (FI) | 2020-02-26 | — | — | EP | claimed |
| US-10189789-B2 | Process for the preparation of androgen receptor antagonists and intermediates thereof | ORION CORPORATION (FI) | 2019-01-29 | — | — | US | claimed |
| US-20180099938-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2018-04-12 | — | — | US | claimed |
| EP-3280710-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | Orion Corporation (FI) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162604-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2016-10-13 | — | — | WO | claimed |
| WO-2026106969-A1 | NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE | UNIVERSITY OF ROCHESTER (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009152025-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | AR, GNRHR, FSHR | CYP4F2 354/4885CYP4A11 126/4885ATR 1799/4885 |
| US-20180099938-A1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | AR, NR5A1, GNRHR | CYP4F2 494/4885CYP4A11 119/4885ATR 2631/4885 |
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | AR, FSHR, PKD1 | CYP4F2 2009/4885CYP4A11 1079/4885ATR 459/4885 |
| US-10189789-B2 | Process for the preparation of androgen receptor antagonists and intermediates thereof | AR, NR5A1, GNRHR | CYP4F2 494/4885CYP4A11 119/4885ATR 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.